Drug Trial Radar · NCT06940791
Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Oct 6, 2023
Primary completion
Feb 2030
Study completion Feb 2030
Sponsor
- Lead sponsor
- Kyorin UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Center, Japan; Ono Pharmaceutical Co., Ltd.; Japan Clinical Oncology Group
- First posted
- Apr 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A double-blind, randomized phase II comparative trial will evaluate the superiority of the investigational treatment (tirabrutinib maintenance therapy) over standard care (observation with placebo) in terms of progression-free survival in patients with newly diagnosed primary central nervous system lymphoma (PCNSL) who have achieved complete response (CR or CRu) following induction therapy with high-dose methotrexate (HD-MTX)-based chemotherapy and have not undergone consolidative whole-brain irradiation. Participants will: Take protocol drug tirabrutinib or a placebo every day until disease progression or experience of unacceptable toxicity. Visit the clinic once every 4 weeks for checkups and tests, as well as protocol drug prescription.
Conditions
- Primary Central Nervous System Lymphoma
Interventions
TirabrutinibDrug
Tirabrutinib (480 mg) taken orally daily at fasting condition
PlaceboDrug
Placebo taken orally daily at fasting condition
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) based on independent review committee (IRC) assessmentTime frame: From the date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 78 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyorin University Hospital
Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.